Framingham Risk Score Calculator
Estimates 10-year risk of hard coronary heart disease events (myocardial infarction or coronary death) using the NCEP ATP III point-based scoring system. Derived from the Framingham Heart Study cohort.
Calculate Framingham Risk Score
Enter the patient’s age, sex, lipid values, blood pressure, smoking status, and treatment status. This score estimates 10-year risk of hard CHD (MI or coronary death) for adults aged 20–79 without prior CHD. Diabetes is considered a CHD risk equivalent in the ATP III framework and is not included in this score — diabetic patients are already considered high risk.
This calculator implements the ATP III hard CHD Framingham Risk Score (MI + coronary death). It does not include diabetes as an input because ATP III considers diabetes a CHD risk equivalent — diabetic patients are automatically classified as high risk (> 20% 10-year risk). This score has been largely supplanted by the ACC/AHA Pooled Cohort Equations (ASCVD Risk Calculator) in US guidelines but remains widely used internationally.
Understanding the Framingham Risk Score
The Framingham Risk Score is derived from the Framingham Heart Study, a landmark longitudinal cohort study that began in 1948 in Framingham, Massachusetts. The ATP III version of the score, published in 2002 by the National Cholesterol Education Program (NCEP), uses a sex-specific point-based system to estimate 10-year risk of “hard” coronary heart disease — defined as myocardial infarction or coronary death.
The score assigns points for age, total cholesterol (age-adjusted), HDL cholesterol, systolic blood pressure (with separate tables for treated and untreated patients), and smoking status (also age-adjusted). Points are summed and mapped to a 10-year risk percentage. Importantly, the cholesterol and smoking point contributions decrease with advancing age, reflecting the diminishing incremental risk these factors confer as age itself becomes the dominant predictor.
Input Variables
Age (20–79 years)
Sex (male / female)
Total cholesterol (mg/dL)
HDL cholesterol (mg/dL)
Systolic BP (mmHg)
BP treatment status (yes / no)
Current smoker (yes / no)
Not included: Diabetes (treated as automatic CHD risk equivalent), LDL-C, family history, race/ethnicity.
Worked Example (Male)
55-year-old male, TC 220, HDL 45, SBP 140 (untreated), non-smoker:
Age 55–59 → 8 pts
TC 200–239, age 50–59 → 3 pts
HDL 40–49 → 1 pt
SBP 140–159, untreated → 1 pt
Non-smoker → 0 pts
Total = 13 pts → 12% 10-year risk
Key distinction: The Framingham Risk Score predicts hard CHD only (MI + coronary death). It does not include stroke, heart failure, or peripheral arterial disease. The 2008 Framingham General CVD Score expands the endpoint to include all CVD manifestations and typically produces higher risk estimates. The 2013 ACC/AHA Pooled Cohort Equations (ASCVD calculator) include both CHD and stroke as endpoints.
Risk Categories & Management Implications
| 10-Year CHD Risk | Category | ATP III LDL-C Goal | Management |
|---|---|---|---|
| < 10% | Low–Moderate | < 160 mg/dL (0–1 RF) < 130 mg/dL (≥ 2 RF) | Therapeutic lifestyle changes; statin if LDL-C persistently above goal |
| 10–20% | Moderately High | < 130 mg/dL (optional: < 100) | Lifestyle + consider statin; lower threshold for drug therapy |
| > 20% | High (CHD equivalent) | < 100 mg/dL (optional: < 70) | Aggressive LDL-C lowering; high-intensity statin strongly recommended |
Under ATP III, the Framingham Risk Score is only calculated for patients with 2 or more major risk factors (other than LDL-C). Patients with 0–1 risk factors generally have a < 10% 10-year risk without needing formal scoring. The major risk factors counted are: cigarette smoking, hypertension (BP ≥ 140/90 or on antihypertensive), low HDL-C (< 40 mg/dL), family history of premature CHD (male first-degree relative < 55, female < 65), and age (men ≥ 45, women ≥ 55). HDL-C ≥ 60 counts as a negative risk factor (subtract 1).
Scoring Criteria in Detail
Age is the single largest contributor to the Framingham score, reflecting the strong independent relationship between advancing age and coronary risk. The point scale ranges from −9 (men age 20–34) to +16 (women age 75–79). This dominant weighting means that younger adults rarely exceed the 10% threshold even with multiple other risk factors — a recognized limitation of the score for identifying at-risk young adults.
Men: 20–34: −9, 35–39: −4, 40–44: 0, 45–49: 3, 50–54: 6, 55–59: 8, 60–64: 10, 65–69: 11, 70–74: 12, 75–79: 13.
Women: 20–34: −7, 35–39: −3, 40–44: 0, 45–49: 3, 50–54: 6, 55–59: 8, 60–64: 10, 65–69: 12, 70–74: 14, 75–79: 16.
Cholesterol points are age-adjusted because the relative contribution of elevated cholesterol to coronary risk diminishes with age (as age itself and other factors become more dominant). The same cholesterol level earns more points in younger patients, reflecting the greater lifetime exposure to atherogenic lipoproteins and the higher relative risk conferred by hyperlipidaemia at younger ages.
For example, a total cholesterol of 240–279 mg/dL scores 9 points in a man aged 20–39 but only 1 point in a man aged 70–79. This design means that elevated cholesterol contributes substantially more to the score — and to the treatment decision — in younger patients.
HDL cholesterol is the only variable in the Framingham Risk Score that can subtract points. HDL ≥ 60 mg/dL earns −1 point, reflecting its established cardioprotective role (reverse cholesterol transport, anti-inflammatory effects). Conversely, low HDL (< 40 mg/dL) adds 2 points, identifying patients with atherogenic dyslipidaemia. HDL points are the same for both men and women and are not age-adjusted.
- ≥ 60 mg/dL: −1 point
- 50–59 mg/dL: 0 points
- 40–49 mg/dL: +1 point
- < 40 mg/dL: +2 points
Blood pressure scoring uses separate tables for treated and untreated patients. Treated hypertension scores higher points at the same SBP level, reflecting the observation that patients requiring antihypertensive medication have a higher residual cardiovascular risk than those with the same BP achieved naturally. The treated-untreated distinction is a unique feature of the Framingham score.
Men untreated: <120: 0, 120–129: 0, 130–139: 1, 140–159: 1, ≥160: 2.
Men treated: <120: 0, 120–129: 1, 130–139: 2, 140–159: 2, ≥160: 3.
Women untreated: <120: 0, 120–129: 1, 130–139: 2, 140–159: 3, ≥160: 4.
Women treated: <120: 0, 120–129: 3, 130–139: 4, 140–159: 5, ≥160: 6.
Like cholesterol, smoking points are age-adjusted. Smoking contributes the most points in younger patients (8 for men age 20–39, 9 for women age 20–39) and decreases with age (1 point for both sexes at age 70–79). This reflects the declining relative (though not absolute) contribution of smoking to CHD risk as age-related risk dominates. Non-smokers receive 0 points at all ages.
Former smokers are scored as non-smokers (0 points). Only current, active tobacco use at the time of assessment scores positive points.
Framingham vs. Pooled Cohort Equations (ASCVD)
Clinical significance: The PCE has replaced the Framingham Risk Score in US practice guidelines for statin therapy decisions. However, the Framingham score remains relevant for international guidelines, for comparison with historical data, and in populations where the PCE may not be well-calibrated. For US primary prevention, the ASCVD Risk Calculator (PCE) is the current standard.
Common Pitfalls & Limitations
Because age dominates the score, younger adults (20–39) rarely exceed the 10% threshold even with heavy smoking, high cholesterol, and hypertension. This means the score may fail to identify young adults with a high lifetime risk who could benefit from early intervention. For younger patients with significant risk factor burdens, consider lifetime risk assessment or non-traditional risk markers (CAC score, family history).
The ATP III Framingham score predicts only hard CHD (MI + coronary death). It does not capture stroke risk, heart failure, or peripheral arterial disease. A patient may have a “low” Framingham score but carry substantial stroke risk due to hypertension and atrial fibrillation. The 2008 Framingham General CVD score and the Pooled Cohort Equations address this limitation by including broader endpoints.
The Framingham Heart Study cohort was predominantly White, from a single New England community. While recalibration studies have shown reasonable performance in some ethnic groups (including African Americans), the score may over- or under-estimate risk in Hispanic, Asian, South Asian, and other populations. The Pooled Cohort Equations partially address this with race-specific equations for African Americans.
The score does not include family history of premature CHD, obesity/BMI, physical inactivity, inflammatory markers (hs-CRP), Lp(a), or renal function. These omissions mean that two patients with identical Framingham scores may have very different actual risk profiles. Consider using risk-enhancing factors (per 2019 ACC/AHA guidelines) to refine the risk estimate when the score falls near a treatment threshold.
Quick Reference Summary
| Variable | Men Range | Women Range | Key Note |
|---|---|---|---|
| Age | −9 to +13 | −7 to +16 | Dominant predictor; age-adjusts TC & smoking |
| Total Cholesterol | 0 to +11 | 0 to +13 | Points decrease with advancing age |
| HDL Cholesterol | −1 to +2 | −1 to +2 | Only variable that subtracts points |
| Systolic BP | 0 to +3 | 0 to +6 | Treated BP scores higher than untreated |
| Smoking | 0 to +8 | 0 to +9 | Points decrease with advancing age |
The Golden Rule: The Framingham Risk Score is a starting point for risk assessment, not the final word. Combine with clinical judgement, risk-enhancing factors, family history, and — when available — subclinical atherosclerosis imaging (CAC score) for a complete risk picture. For US practice, the Pooled Cohort Equations (ASCVD calculator) are now the preferred tool for guiding statin therapy decisions.
Disclaimer & References
For Educational Purposes Only. This calculator and the accompanying clinical information are intended as educational tools for healthcare professionals. They do not replace clinical judgement. Results should be interpreted in the full clinical context. Lab reference ranges vary by institution — verify with your own laboratory. Drug dosages should be confirmed against current prescribing information.
References
- Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the NCEP Expert Panel (ATP III). JAMA. 2001;285(19):2486-2497. DOI: 10.1001/jama.285.19.2486
- Wilson PWF, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837-1847. DOI: 10.1161/01.CIR.97.18.1837
- D’Agostino RB Sr, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117(6):743-753. DOI: 10.1161/CIRCULATIONAHA.107.699579
- Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the NCEP ATP III guidelines. Circulation. 2004;110(2):227-239. DOI: 10.1161/01.CIR.0000133317.49796.0E
- D’Agostino RB Sr, Grundy S, Sullivan LM, Wilson P. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA. 2001;286(2):180-187. DOI: 10.1001/jama.286.2.180
- Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk. Circulation. 2014;129(25 Suppl 2):S49-S73. DOI: 10.1161/01.cir.0000437741.48606.98
- Kannel WB, McGee D, Gordon T. A general cardiovascular risk profile: the Framingham Study. Am J Cardiol. 1976;38(1):46-51. DOI: 10.1016/0002-9149(76)90061-8